MedTrace Logo

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

NCT03117036 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-05-21

No results posted yet for this study

Summary

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Conditions

  • Lymphoma, Non-Hodgkin
  • Lymphoma, Hodgkin

Interventions

DRUG

Chemotherapy

Systemic chemotherapy with curative intent

Sponsors & Collaborators

  • Samsung Genomic Institute

    collaborator UNKNOWN

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Seok Jin Kim, MD, PhD · Samsung Medical Center

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2026-12-28
Completion
2026-12-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03117036 on ClinicalTrials.gov